Who Paid My Doc
Cynthia Duncan
Clinical Nurse Specialist, Psychiatric/Mental Health Tyrone, GA Clinical Nurse Specialist
NPI 1972671634 CMS profile 10530821
120 Handley Rd, Tyrone, GA 30290
General payments
$5,558
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Cynthia Duncan of Tyrone, GA is reported in the CMS Open Payments database as having received $5,558 across 303 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 90th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,428 | 74 | |
| 2024 | General | $902 | 49 | |
| 2023 | General | $1,393 | 74 | |
| 2022 | General | $1,194 | 68 | |
| 2021 | General | $641 | 38 |
Beside peers
- Cynthia Duncan
- Clinical Nurse Specialist, Psychiatric/Mental Health median
- Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
- National median
In program year 2025, general payments to Cynthia Duncan were reported at $1,428. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.
Show as a table
| Year | Cynthia Duncan | Clinical Nurse Specialist, Psychiatric/Mental Health median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $641 | $153 | $44–$540 | $132 |
| 2022 | $1,194 | $207 | $60–$748 | $149 |
| 2023 | $1,393 | $197 | $55–$898 | $160 |
| 2024 | $902 | $189 | $49–$804 | $164 |
| 2025 | $1,428 | $245 | $78–$929 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
358
Drug cost
$420,804
Branded share of claims
34.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Austedo Xr Deutetrabenazine | Brand | 31 | $352,703 | |
| Vraylar Cariprazine Hcl | Brand | 13 | $31,925 | |
| Caplyta Lumateperone Tosylate | Brand | 11 | $22,854 | |
| Belsomra Suvorexant | Brand | 12 | $7,808 | |
| Desvenlafaxine Succinate Er Desvenlafaxine Succinate | Brand | 16 | $1,027 | |
| Temazepam | Generic | 13 | $899 | |
| Buspirone Hcl | Generic | 26 | $862 | |
| Trazodone Hcl | Generic | 37 | $511 | |
| Lamotrigine | Generic | 32 | $373 | |
| Bupropion Xl Bupropion Hcl | Brand | 27 | $357 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 13 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VRAYLAR |
|
$153 | 13 | — |
| REXULTI |
|
$130 | — | — |
| Qelbree |
|
$95 | — | — |
| JORNAY PM |
|
$88 | — | — |
| Austedo XR |
|
$87 | 31 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 13 in the dashboard with a free accountRecords
303 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Nurse Specialist, Psychiatric/Mental Health in Georgia
Namita Patel
Clinical Nurse Specialist, Psychiatric/Mental Health · Marietta, GA
Beverly Philson
Clinical Nurse Specialist, Psychiatric/Mental Health · Atlanta, GA
Marcia Younker
Clinical Nurse Specialist, Psychiatric/Mental Health · Jackson, GA
Carol Baker
Clinical Nurse Specialist, Psychiatric/Mental Health · Macon, GA
Pamela Roberson
Clinical Nurse Specialist, Psychiatric/Mental Health · Marietta, GA
Maria Jorgenson
Clinical Nurse Specialist, Psychiatric/Mental Health · Lawrenceville, GA
Related records
Clinical Nurse Specialist, Psychiatric/Mental Health in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Nurse Specialist, Psychiatric/Mental Health
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.